Despite this potential, the clinical significance of CLDN6 expression in advanced-stage high-grade serous ovarian carcinoma (HGSC)-specifically its role in platinum resistance-remains poorly understood. This evidence concerns the gene CLDN6 and ovarian serous carcinoma.